Key result
This review provides an overview of the efficacy and safety of novel oral anticoagulants compared to classic anticoagulants for the treatment and primary prevention of venous thromboembolism.
Why the study?
Do novel oral anticoagulants (NOACs) improve outcomes in patients with venous thromboembolism compared to classic anticoagulants?
Do novel oral anticoagulants (NOACs) improve outcomes in patients with venous thromboembolism compared to classic anticoagulants?
Answers are grounded in this paper and cite their sources.
This review summarizes the role and evidence for novel oral anticoagulants (NOACs) in the treatment and primary prevention of venous thromboembolism.
Thrombo-embolism of the venous system consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE) is common and associated with high morbidity and mortality. Symptomatic venous thromboembolism (VTE) manifests in about 1/3 of cases as PE and 2/3 as DVT. There is a strongly compound between early mortality after venous VTE and PE, age, malignancies and cardiovascular diseases. Anticoagulation therapy is the main therapeutic approach for the treatment of acute VTE and to prevent recurrent VTE events. For decade's classic anticoagulants like heparin, low-molecular-weight heparins (LMWHs), fondaparinux, and vitamin K antagonists have been the gold standards in therapy and are widely used. Novel oral anticoagulants (NOAC) like the direct thrombin inhibitor (dabigatran etexilate) and the direct factor Xa inhibitors (e.g. rivaroxaban, apixaban, and edoxaban) have been introduced to overcome the drawbacks of vitamin K antagonists. The efficacy and safety of these NOAC have been investigated in several randomized trials. Here we want to give an overview about the NOACS in the treatment of acute and chronic VTE and their use for primary prevention of acute VTE.
No takes yet. Share an insight, caveat, or question.
Akin et al. (2015) conducted a review in Venous Thromboembolism (VTE). Novel oral anticoagulants (NOACs) vs. Classic anticoagulants (heparin, LMWHs, fondaparinux, vitamin K antagonists) was evaluated. This review provides an overview of the efficacy and safety of novel oral anticoagulants compared to classic anticoagulants for the treatment and primary prevention of venous thromboembolism.
Synapse has enriched 10 related papers. Consider them for comparative context: